A61P 37 - Drugs for immunological or allergic disorders

Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/2001
11/27/2001	US6322790 Treatment of primary and metastatic noeplastic diseases and infectious diseases; administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule
11/26/2001	CA2316405A1 Modulation of inflammation by protease products
11/25/2001	CA2309518A1 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
11/25/2001	CA2309424A1 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
11/25/2001	CA2309417A1 Apoptotic entities for use in treatment of endothelium dysfunction disorders
11/22/2001	WO2001088199A2 Identification and modulationof of a t helper-1 and t helper-2 cells
11/22/2001	WO2001088159A2 Cd28 synthebody for the modulation of immune responses
11/22/2001	WO2001088129A1 Anti-angiogenic polypeptides
11/22/2001	WO2001088128A1 Ssa-56kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
11/22/2001	WO2001088116A2 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods
11/22/2001	WO2001088108A1 Neuronal serine-threonine protein kinase
11/22/2001	WO2001088106A2 Novel deoxyribonucleside kinase enzyme multi-substrate variants
11/22/2001	WO2001088085A2 Novel bee venom polypeptides and methods of use thereof
11/22/2001	WO2001087982A2 Immunotoxin fusion proteins and means for expression thereof
11/22/2001	WO2001087981A2 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
11/22/2001	WO2001087979A2 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
11/22/2001	WO2001087977A2 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
11/22/2001	WO2001087966A1 A new polypeptide-human pax protein 22 and the polynucleotide encoding it
11/22/2001	WO2001087964A1 A new polypeptide- human gap connexin 15 and the polynucleotide encoding it
11/22/2001	WO2001087963A1 A new polypeptide- human ribosomal protein s18-12 and the polynucleotide encoding it
11/22/2001	WO2001087962A1 A new polypeptide-human pax protein 11 and the polynucleotide encoding it
11/22/2001	WO2001087961A1 A new polypeptide-human pax protein 11.4 and the polynucleotide encoding it
11/22/2001	WO2001087960A1 A new polypeptide-human kruppel-related dna-binding protein 10 and the polynucleotide encoding it
11/22/2001	WO2001087959A1 A new polypeptide-human pax protein 11.9 and the polynucleotide encoding it
11/22/2001	WO2001087935A2 Methods of modulating angiogenesis by regulating the expression of pituitary tumor transforming gene (pttg)
11/22/2001	WO2001087923A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
11/22/2001	WO2001087922A2 Derivatisation of proteins in aqueous solution
11/22/2001	WO2001087890A1 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
11/22/2001	WO2001087889A1 Crf receptor antagonists and methods relating thereto
11/22/2001	WO2001087886A1 Crf receptor antagonists and methods relating thereto
11/22/2001	WO2001087884A2 Polyketide derivatives
11/22/2001	WO2001087883A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
11/22/2001	WO2001087877A1 Novel thiophenamide compounds
11/22/2001	WO2001087870A1 Hydroxamic acid derivatives
11/22/2001	WO2001087849A2 Modulators of tnf- alpha signaling
11/22/2001	WO2001087846A2 Tricyclic pyrazole derivatives as protein kinase inhibitors
11/22/2001	WO2001087844A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
11/22/2001	WO2001087839A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001	WO2001087828A1 N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
11/22/2001	WO2001087823A1 Novel aryl, alkenyl, and alkynl 4-dedimethylaminotetracycline derivatives
11/22/2001	WO2001087810A1 Methods for the production of d-chiro-inositol and the use of d-chiro-inositol obtained therefrom
11/22/2001	WO2001087338A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	WO2001087337A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	WO2001087333A2 Immune system stimulating means
11/22/2001	WO2001087331A1 Pharmaceuticals for depressing autoimmune disorders by idiotype binding fragments of anti-idiotypic antibodies
11/22/2001	WO2001087330A2 Compositions and methods for achieving immune suppression
11/22/2001	WO2001087325A1 Method to increase class i presentation of exogenous antigens by human dendritic cells
11/22/2001	WO2001087311A1 Immunopotentiator
11/22/2001	WO2001087280A2 Means for treating attacks of auto-immune diseases
11/22/2001	WO2001087254A1 Use of ellagic acid as anti-pollution cosmetic agent
11/22/2001	WO2001087234A2 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
11/22/2001	WO2001087039A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
11/22/2001	WO2001055333A8 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides
11/22/2001	WO2001046128A3 Tryptase inhibitors
11/22/2001	WO2001042246A3 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
11/22/2001	WO2001038355A3 Method of forming a peptide-receptor complex with zsig33 and therapeutic use thereof
11/22/2001	WO2001035995A3 Tr3-specific binding agents and methods for their use
11/22/2001	WO2001035991A3 Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
11/22/2001	WO2001034192A3 Improved method of immunization
11/22/2001	WO2001034185A3 Induction of mucosal immunity by vaccination via the skin route
11/22/2001	WO2001030781A3 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
11/22/2001	WO2001027268A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
11/22/2001	WO2001027146A3 Chemokine receptor
11/22/2001	WO2001014564A3 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
11/22/2001	WO2001012607B1 Pharmaceutical compositions comprising 4-quinolones for treating cancers
11/22/2001	WO2000055633A9 Methods of screening for colorectal cancer modulators
11/22/2001	WO2000047713A9 Genes encoding the 5h7 antibody and methods for conferring programmed cell death properties to cells
11/22/2001	WO2000010600A9 Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
11/22/2001	US20010044937 Transgenic intracytoplasmic sperm injection, retroviral gene transfer, intracytoplasmic nuclear injection, and pronuclear injection; useful as models for human disease/diagnosis, assessing safety and efficiency of drug and gene therapy
11/22/2001	US20010044547 From l-mannonic-gamma-lactone intermediates; for prophylaxis of HIV/AIDS HIV
11/22/2001	US20010044538 Mitogen-activated protein (MAP) kinase; treating inflammatory diseases; compounds such as 3-(4-fluorophenyl)-1-hydroxy-2-(pyridin-4-yl)-1H-pyrrolo(3,2-b)pyridine
11/22/2001	US20010044523 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
11/22/2001	US20010044522 Polypeptides, antibodies against them and nucleic acids encoding them; detecting activated CD4+ T-cells to diagnose a disease or condition of the immune system; screening for immunosuppressants
11/22/2001	US20010044471 Hydrogenation of racemic 6-alkoxy-1H-indene-1,2(3H)-dione-2-oxime, with chiral acid, resolution, alkylation, bromination, carboxamidation
11/22/2001	US20010044442 Dimethoxy quinazolines for treating diabetes
11/22/2001	US20010044436 Bicyclic inhibitors of glycogen synthase kinase 3
11/22/2001	US20010044416 Administering an antigen and a CD4+ T helper (Th2) cell immunostimulatory nucleic acid mucosally or dermally to produce an antigen specific immune response; treating autoimmune diseases, cancer, infections
11/22/2001	US20010043915 Method for administering a cytokine to the central nervous system and the lymphatic system
11/22/2001	DE10023484A1 New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
11/22/2001	DE10020667A1 Neue Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln New benzoxazine and benzothiazine derivatives and their use in medicaments
11/22/2001	CA2781858A1 Modulators of tnf-.alpha. signaling
11/22/2001	CA2409746A1 Immunotoxin fusion proteins and means for expression thereof
11/22/2001	CA2409740A1 Novel aryl, alkenyl, and alkynyl 4-dedimethylaminotetracycline desrivatives
11/22/2001	CA2409414A1 Ssa-56kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
11/22/2001	CA2409225A1 Tricyclic pyrazole derivatives
11/22/2001	CA2409154A1 Compositions, kits, and methods for identification and modulation of t helper-1 and t helper-2 cells and diseases associated therewith
11/22/2001	CA2409035A1 Hydroxamic acid derivatives
11/22/2001	CA2408745A1 Anti-angiogenic polypeptides
11/22/2001	CA2408691A1 Compositions and methods for achieving immune suppression
11/22/2001	CA2408617A1 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
11/22/2001	CA2408530A1 Novel deoxynucleoside kinase enzyme variants
11/22/2001	CA2408513A1 Immunomodulatory human mhc class ii antigen-binding polypeptides
11/22/2001	CA2408408A1 Modulators of tnf- alpha signaling
11/22/2001	CA2408383A1 Use of ellagic acid as anti-pollution cosmetic agent
11/22/2001	CA2408373A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
11/22/2001	CA2408360A1 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
11/22/2001	CA2407259A1 Polyketide derivatives
11/22/2001	CA2407258A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001	CA2407104A1 Method to increase class i presentation of exogenous antigens by human dendritic cells
11/22/2001	CA2406013A1 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers

1 ... 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 ... 1172